Diffusion and contrast-enhancement MRI phenotypes associated with immune checkpoint inhibitor exposure and with immune cell infiltration in brain metastases

By sjmartinez • March 23, 2025

Sanvito F, Nocera G, Wang Z, Shiuan E, Sun L, Oshima S, Kim A, Kryukov I, Shao G, Cho NS, Salamon N, Ellingson BM, Prins R, Kim W, Yao J. Diffusion and contrast-enhancement MRI phenotypes associated with immune checkpoint inhibitor exposure and with immune cell infiltration in brain metastases. Neuro Oncol. 2025 Mar 22:noaf084. doi: 10.1093/neuonc/noaf084. Epub ahead of print. PMID: 40119850.

Tags: Brain metastasis, diffusion imaging, Fellow, Hematology/Oncology, immune checkpoint inhibitors, immunotherapy, Magnetic resonance imaging, Publications

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]

CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy

Marshalek JP, Qing X, Tomassetti S. CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy. World J Oncol. 2025[...]

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]